Physician
Medical Care INC
Medical Care INC was paid $1.86M by Medicaid between Jan 2018 and Dec 2024, across 30 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.
33Billing provider infoMEDICAL CARE INC
GOLDSBORO, NC 27534
GOLDSBORO, NC 27534
33aNPI1962673673assigned 03/20/2008
33bProvider typeFamily Medicine Physician
28Total paid$1.86M
24GClaims54,992
24DCodes billed30
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in North Carolina
Rank by total paid#69 of 960
Median peer was paid$135K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,991 | $327K | |
| 2019 | 7,400 | $354K | |
| 2020 | 5,571 | $271K | |
| 2021 | 9,072 | $270K | |
| 2022 | 8,050 | $313K | |
| 2023 | 7,281 | $187K | |
| 2024incomplete | 7,627 | $137K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 41% | 14,512 | 9,397 | $757K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 7,141 | 3,655 | $348K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 9,396 | 6,323 | $342K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 13% | 3,580 | 2,711 | $234K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.2% | 621 | 327 | $60K |
| 99199 | Unlisted special service, procedure or report | 2.0% | 10,138 | 9,951 | $37K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.2% | 783 | 571 | $22K |
| 80305 | <1% | 1,644 | 1,036 | $16K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 366 | 272 | $16K |
| 99205 | Prolong outpt/office vis | <1% | 75 | 62 | $9K |
| 82947 | <1% | 3,308 | 2,337 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 64 | 55 | $3K |
18 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 710 | $2K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 113 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 206 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 38 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 42 | $515.42 |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 15 | $439.67 |
| 99401 | <1% | 17 | $303.40 | |
| 87660 | <1% | 49 | $148.44 | |
| 81003 | <1% | 1,770 | $116.34 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 19 | $48.07 |
| 80061 | Lipid panel | <1% | 107 | $16.53 |
| 3074F | 0% | 24 | $0.00 | |
| 1111F | 0% | 108 | $0.00 | |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | 0% | 35 | $0.00 |
| 3075F | 0% | 16 | $0.00 | |
| 3079F | 0% | 17 | $0.00 | |
| 3008F | 0% | 51 | $0.00 | |
| 3078F | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTABE, WILSON (OWNER)